Tasmanian devils, those quirky marsupial scavengers, are facing a dire threat: a contagious cancer that has decimated their population. But amidst this grim scenario, a beacon of hope emerges through a groundbreaking research partnership. The Colossal Foundation and the University of Tasmania have joined forces to tackle the devil facial tumour disease (DFTD), a formidable challenge that has already claimed the lives of approximately 80% of wild devils since its discovery in 1996. This disease, a cunning duo of cancers (DFT1 and DFT2), spreads through bites during feeding and mating, resulting in tumours that grow around the mouth and face, ultimately leading to starvation and death.
The partnership is a multifaceted approach, employing two innovative strategies. Firstly, they're developing an oral bait vaccine, a clever tactic to train the devil's immune system to combat both cancers. This vaccine, crafted by Andrew Flies and his team at the Menzies Institute for Medical Research, aims to provide a protective shield without the need for trapping and injecting each individual devil. The Colossal Foundation's involvement is pivotal, as they've established a colony of fat-tailed dunnarts, a mouse-sized marsupial relative, in Hobart. This colony serves as a crucial testing ground for the vaccine's safety before any trials on devils commence.
The challenges of working with an endangered species and the scarcity of marsupial research tools have slowed progress, but the partnership offers a glimmer of hope. By collaborating, they can accelerate vaccine development and explore gene-editing strategies in parallel. This includes targeting the LZTR1 gene, which researchers believe plays a pivotal role in the origin of the tumours. The idea is to edit this gene to reduce the devils' susceptibility to the cancers, a potentially transformative approach.
The implications of this research extend far beyond the fate of Tasmanian devils. As apex scavengers, their decline disrupts the delicate balance of the ecosystem, allowing feral cats to spread unchecked. This partnership, therefore, represents not just a fight against a deadly disease but a broader effort to preserve the ecological harmony of Tasmania. While the vaccine must still undergo safety trials, this collaboration exemplifies the power of scientific innovation and collaboration in addressing complex environmental challenges.
